Drug intelligence / Profile preview

human insulin + insulin analogues

Development stage
Unknown
Lead developer
Genentech
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous (in Some Hospital Settings)
01

Overview

This is a combination of human insulin and one or more insulin analogues. Human insulin is a recombinant form of the natural hormone produced by pancreatic beta cells and is used to regulate blood glucose levels. Insulin analogues are genetically engineered variants of human insulin with modifications in their amino acid sequence to alter pharmacokinetic properties such as onset and duration of action. These combinations are designed to provide both rapid (or short) and intermediate or long-acting effects for optimal glycemic control in diabetes mellitus. The mechanism involves stimulating peripheral glucose uptake (mainly by skeletal muscle and fat), inhibiting hepatic glucose production, suppressing lipolysis and proteolysis, and enhancing protein synthesis[3][4][5][6]. These products are primarily indicated for the treatment of type 1 diabetes mellitus but are also used in type 2 diabetes when oral agents are insufficient[1][4].

Brand names
Humulin M3NovoMixHumalog MixMixtard 30Mixtard30Mixtard-30Mixtard 40 PenfillMixtard40 PenfillMixtard-40 PenfillMixtard 50 PenfillMixtard50 PenfillMixtard-50 PenfillNovoLog Mix 70/30
Other names
biphasic insulin
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on human insulin + insulin analogues.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human insulin + insulin analogues.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call